Leerink Swann Starts Santarus (SNTS) at Outperform
Tweet Send to a FriendGet Alerts SNTS Hot Sheet
Price: $21.75 -2.38%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade SNTS Now!
Leerink Swann initiates coverage on Santarus (NASDAQ: SNTS) with a Outperform with a valuation range of $15-$16.
The firm comments, "We are initiating coverage of SNTS with an Outperform rating for several reasons including: (1) positive KOL feedback on the recently approved Uceris for ulcerative colitis (UC) -- we forecast $235m in '18E sales; (2) near-term catalysts -- a post-market Uceris study and potential Cycloset (HAE) patent issuance -- provide upside to our valuation; and (3) Zegerid for heartburn - mkt recapture and modest damages provide significant cash flow for biz development. We value SNTS at $15-16/shr based on DCF, and bull case catalysts could drive valuation to $18-19/shr."
For an analyst ratings summary and ratings history on Santarus click here. For more ratings news on Santarus click here.
Shares of Santarus closed at $12.93 yesterday, with a 52 week range of $4.19-$13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We are initiating coverage of SNTS with an Outperform rating for several reasons including: (1) positive KOL feedback on the recently approved Uceris for ulcerative colitis (UC) -- we forecast $235m in '18E sales; (2) near-term catalysts -- a post-market Uceris study and potential Cycloset (HAE) patent issuance -- provide upside to our valuation; and (3) Zegerid for heartburn - mkt recapture and modest damages provide significant cash flow for biz development. We value SNTS at $15-16/shr based on DCF, and bull case catalysts could drive valuation to $18-19/shr."
For an analyst ratings summary and ratings history on Santarus click here. For more ratings news on Santarus click here.
Shares of Santarus closed at $12.93 yesterday, with a 52 week range of $4.19-$13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Iberia Capital Starts Synergy Resources Corporation (SYRG) at Outperform
- Santarus President & CEO Gerald Proehl Honored as San Diego Ernst & Young Entrepreneur of the Year 2013 in Life Sciences
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
